Canaccord Genuity Rates Definium Therapeutics (DFTX) buy
Canaccord Genuity maintains its buy rating on Definium Therapeutics, setting a price target of $58.00, a 23.30% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Canaccord Genuity rated Definium Therapeutics, Inc. ($DFTX) "buy" with a $58 price target on June 30, 2026.
Since the rating, $DFTX is down 5.4% after 1 week, down 5.4% after 1 month and down 31.8% to date (from the $47.04 close on Jun 30, 2026).
DFTX
Definium Therapeutics, Inc.
Key Points
- Canaccord Genuity reiterated its buy rating on Definium Therapeutics, setting a target of $58.00 while the stock trades at $47.04.
- Canaccord Genuity's $58 price target implies 23.30% upside from Definium Therapeutics, Inc.'s ($DFTX) current $47.04 share price.
- Currently, Definium Therapeutics has a market cap of about $5.28 billion and is focused on developing treatments for brain health disorders.
- The stock has a mean price target of $71.65 from 17 analysts, showing strong confidence in its future performance.
Get $DFTX trade alerts by text
We text you when insiders, Congress or big funds trade $DFTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures
Analysts Set New Price Targets
On June 30, 2026, Canaccord Genuity reiterated its buy rating on Definium Therapeutics, Inc. (DFTX) on the NasdaqGS, setting a price target of $58.00. The stock was trading at $47.04 at the time of the announcement. This suggests a potential upside for investors, as the current price is significantly below the target.
Canaccord Genuity vs. the S&P 500
Hypothetical returns from Canaccord Genuity's disclosed trades, not real profit or advice. How we model this.
What Changed in the Position
The reiteration from Canaccord Genuity maintains their positive outlook on the company. The firm sees continued value in Definium, especially as it develops treatments for brain health disorders. The previous target was not available, but the new target of $58.00 indicates a strong belief in the company’s future.
Institutional Insights
No peer funds reported adjustments to their positions in Definium Therapeutics, which highlights Canaccord Genuity's unique stance on the stock in the current market environment.
How Definium Therapeutics, Inc. Stock Has Traded
Definium Therapeutics is currently trading at $47.04, which is close to its 52-week high of $49.70. The stock has shown significant growth since hitting a low of $9.35 in the past year. This upward trend reflects investor optimism about the company’s clinical trials and product pipeline.
$DFTX price target
Definium Therapeutics, Inc. daily closes and this analyst's $58 target. Not advice.
Recent Earnings
Definium Therapeutics is expected to report its next earnings on November 5, 2026. This upcoming report will be crucial in assessing the company's progress in its clinical trials and overall financial health.
Insider Buying and Selling at Definium Therapeutics, Inc.
Insider selling occurred recently, with Chief Financial Officer Brandi Roberts selling 3,013 shares at an average price of $45.03 on June 25, 2026, totaling about $135,675. Chief Commercial Officer Matthew Wiley also sold 2,867 shares at the same average price, amounting to approximately $129,101. Both transactions were planned and do not imply negative sentiment towards the company.
Analysts Set New Price Targets
Definium has received attention from various analysts recently. On October 9, 2026, JP Morgan initiated coverage with an Overweight rating and a target of $84.00. Canaccord Genuity maintained its buy rating with a target increase from $64.00 to $78.00 on September 15, 2026. Other firms like Baird and HC Wainwright also reiterated their positive ratings, indicating a solid consensus among analysts.
What Definium Therapeutics, Inc. Does
Definium Therapeutics, Inc. focuses on developing innovative treatments for brain health disorders. Its lead product candidates are in various stages of clinical trials, which could significantly impact the company's future performance. The recent analyst ratings suggest that investors are optimistic about these developments.
What's Ahead for Definium Therapeutics, Inc.
Investors will be keen to see how Definium performs in its upcoming earnings report on November 5, 2026. The reiteration of the buy rating by Canaccord Genuity highlights confidence in the company's future, but the 13F filings will reflect past positions and may not represent the current state of investments.
Related Filing Alerts
Source: Canaccord Genuity's rating change on $DFTX (Jun 30, 2026). Written by software, not financial advice. How we make alerts